Sinovac Biotech (Sinovac Biotech) Gross Margin % : -34.19% (As of Jun. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Sinovac Biotech's Gross Profit for the six months ended in Jun. 2023 was $-48.0 Mil. Sinovac Biotech's Revenue for the six months ended in Jun. 2023 was $140.4 Mil. Therefore, Sinovac Biotech's Gross Margin % for the quarter that ended in Jun. 2023 was -34.19%.

Warning Sign:

Sinovac Biotech Ltd gross margin has been in long-term decline. The average rate of decline per year is -6.3%.

The historical rank and industry rank for Sinovac Biotech's Gross Margin % or its related term are showing as below:

SVA' s Gross Margin % Range Over the Past 10 Years
Min: -46.96 Med: 81.11 Max: 94.47
Current: -46.96

During the past 13 years, the highest Gross Margin % of Sinovac Biotech was 94.47%. The lowest was -46.96%. And the median was 81.11%.

SVA's Gross Margin % is not ranked
in the Biotechnology industry.
Industry Median: 59.4 vs SVA: -46.96

Sinovac Biotech had a gross margin of -34.19% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Sinovac Biotech was -6.30% per year.

Sinovac Biotech Gross Margin % Historical Data

The historical data trend for Sinovac Biotech's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Gross Margin % Chart

Sinovac Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Gross Margin %

Get a 7-Day Free Trial

89.23

86.80

86.84

94.47

54.15

Sinovac Biotech Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Gross Margin %	Get a 7-Day Free Trial															94.25	94.75	79.02	-53.35	-34.19

Competitive Comparison of Sinovac Biotech's Gross Margin %

For the Biotechnology subindustry, Sinovac Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinovac Biotech's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's Gross Margin % falls into.

Sinovac Biotech Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Sinovac Biotech's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )	=	Gross Profit (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	808.3	/	1492.761
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(1492.761 - 684.456)	/	1492.761
	=	54.15 %

Sinovac Biotech's Gross Margin for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )	=	Gross Profit (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-48	/	140.404
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(140.404 - 188.409)	/	140.404
	=	-34.19 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Sinovac Biotech (NAS:SVA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Sinovac Biotech had a gross margin of -34.19% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Sinovac Biotech Gross Margin % Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinovac Biotech (Sinovac Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085

Website

http://www.sinovac.com

Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.

Executives

Lily Wang	director, 10 percent owner, officer: Chief Financial Officer	300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc	10 percent owner	PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong	director, 10 percent owner, officer: President and CEO
Terry G Bowering	director, 10 percent owner, officer: President, CEO	10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6